In NGS based studies, Rossi et al. suggested a probable role of activating mutations in NRAS, KRAS or BRAF genes for PCD progression from MGUS to smoldering and symptomatic myeloma [36]. The gene discussed is BRAF; the disease is plasma cell myeloma.